A phase II trial to assess the impact of b2 adrenergic blockade in immune checkpoint inhibitor (ICI)- refractory metastatic triple negative breast cancer (mTNBC)

被引：0
|
作者：
Gandhi, Shipra [1 ]
Roy, Arya Mariam [1 ]
Minderman, Hans [1 ]
Rosario, Spencer [1 ]
Repasky, Elizabeth A. [1 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1141
引用
收藏
页数：1
相关论文
共 50 条
  • [21] LCCC 1525: A phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer (mTNBC)
    Anders, C. K.
    Moore, D.
    Sambade, M.
    Cuaboy, L.
    Garrett, A.
    Woodcock, M.
    McKinnon, K.
    Cowens, K.
    Bortone, D.
    Calhoun, B.
    Carey, L.
    Dees, C.
    Jolly, T.
    Muss, H.
    Reeder-Hayes, K.
    Kaltman, R.
    Jankowitz, R.
    Gudena, V.
    Olajide, O.
    Perou, C.
    Vincent, B.
    Serody, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [22] A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC)
    Isakoff, Steven J.
    Tung, Nadine M.
    Yin, Jun
    Tayob, Nabihah
    Parker, Joanne
    Rosenberg, Julie
    Bardia, Aditya
    Spring, Laura
    Park, Hannah
    Collins, Maya
    Barry, William T.
    Severgnini, Mariano
    Peterkin, Doris
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [23] N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)
    Moreno-Aspitia, A.
    Rowland, K. M., Jr.
    Allred, J. B.
    Liu, H.
    Stella, P. J.
    Gross, H. M.
    Soon, G. S.
    Karlin, N. J.
    Perez, E. A.
    CANCER RESEARCH, 2012, 72
  • [24] A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP).
    Sun, Kai
    Ensor, Joe E.
    Xu, Yitian
    Zhang, Licheng
    Guerrero, Carlo
    Niravath, Polly Ann
    Patel, Tejal Amar
    Geyer, Charles E.
    Jain, Dharamvir
    Teh, Bin S.
    Farach, Andrew M.
    Sultenfuss, Mark
    Gupta, Nakul
    Schwartz, Mary R.
    Haley, Susan
    Mejia, Jamie
    Butler, E. Brian
    Bernicker, Eric
    Chen, Shu-Hsia
    Chang, Jenny Chee Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer
    Shafique, Michael
    IsmailKhan, Roohi
    Extermann, Martine
    Sullivan, Dan
    Goodridge, Dawn
    Boulware, David
    Hogue, Deanna
    Soliman, Hatem
    Khong, Hung
    Han, Hyo S.
    ONCOLOGIST, 2019, 24 (07): : 887 - +
  • [26] A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Graham, Noah
    Bi, Kevin
    Park, Jihye
    Fu, Jingxin
    Keenan, Tanya
    Richardson, Edward Thomas
    Pastorello, Ricardo
    Lange, Paulina
    Attaya, Victoria
    Wesolowski, Robert
    Sinclair, Natalie
    Lucas, Zarah
    Lo, Steve
    Tung, Nadine
    Faggen, Meredith
    Kaufman, Peter A.
    Block, Caroline C.
    Briccetti, Fred
    Toke, Madhavi
    Chen, Wendy
    Wucherpfennig, Kai
    Marx, Sascha
    Agudo, Judith
    Guerriero, Jennifer L.
    Schnitt, Stuart
    Lin, Nancy U.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tayob, Nabihah
    Van Allen, Eliezer
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [27] Predicting the likelihood of response in PDL-1 positive metastatic triple negative breast cancer treated with an immune checkpoint inhibitor
    Aldrich, Jeffrey
    Hu, Thomas
    Switchenko, Jeffrey
    Coskun, Ahmet
    Gokmen-Polar, Yesim
    Badve, Sunil
    Bhave, Manali
    CANCER RESEARCH, 2023, 83 (05)
  • [28] A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia G.
    D'Adamo, David R.
    Aktan, Gursel
    Tsai, Michaela L.
    O'Regan, Ruth
    Kaufman, Peter A.
    Wilks, Sharon
    Andreopoulou, Eleni
    Patt, Debra A.
    Yuan, Yuan
    Wang, Grace
    Xing, Dongyuan
    Kleynerman, Ella
    Karantza, Vassiliki
    Diab, Sami
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy
    Wang, Zhiren
    Cordova, Leyla Estrella
    Chalasani, Pavani
    Lu, Jianqin
    MOLECULAR PHARMACEUTICS, 2022, 19 (12) : 4665 - 4674
  • [30] A phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC)
    McArthur, Heather L.
    Barker, Christopher Andrew
    Gucalp, Ayca
    Lebron-Zapata, Lizza
    Wen, Yong Hannah
    Kallman, Cindy
    D'Agnolo, Alessandro
    Rodine, Micaela
    Arnold, Brittany
    Zhang, Zhigang
    Ho, Alice Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345